Testing immune-suppressing treatment to preserve insulin in newly diagnosed type 1 diabetes

This trial is testing whether a treatment called anti-thymocyte globulin (ATG), given as an initial dose, followed by either a daily oral medication called verapamil or injections of adalimumab, can help preserve your body's natural insulin production in the first two years after a type 1 diabetes diagnosis. The goal is to see whether this combination approach can slow down the autoimmune process that damages the insulin-producing cells in your pancreas.

When someone is first diagnosed with type 1 diabetes, their immune system is actively attacking the cells that make insulin. If researchers can slow or stop this attack early on, it might mean that your pancreas can keep producing some of its own insulin for longer, which could make diabetes easier to manage and reduce complications over time.